Comparator choice scuppers BI/Lilly's Trajenta assessment in Germany
This article was originally published in Scrip
Executive Summary
Industry representatives are calling for the involvement of an independent comparator designator after IQWiG, Germany's Institute for Quality and Efficiency in Healthcare, was unable to conclude that Boehringer Ingelheim/Lilly's DPP4 inhibitor Trajenta (linagliptin) offered any additional benefit over comparators for glycaemic control in type 2 diabetes patients. The decision came after the firms chose Merck & Co's DPP-4 inhibitor Januvia (sitagliptin) as a comparator, rather than those prescribed by the G-BA, the committee in charge of reimbursement.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.